On March 6, 2024 Onchilles Pharma, a private biotech company developing cancer therapeutics that leverage a novel innate immune mechanism of action, reported that it will unveil preclinical data on systemically delivered N17465 in an oral presentation and new preclinical data for tumor-directed N17350 in a poster presentation at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2024, to be held April 5 to 10 at the San Diego Convention Center (Press release, Onchilles Pharma, MAR 6, 2024, View Source [SID1234640930]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
N17350 and N17465 are first-in-class biologic therapeutics that harness the potent efficacy of the innate immune system and have the potential to become a major new treatment modality for a wide range of cancer types. The company plans to start first-in-human clinical trials for N17350 in 2024.
Presentation Details
Talk Title : N17465, a systemically deliverable elastase, attenuates tumorigenesis and stimulates anti-tumor immunity
Session : Drug Discovery 2: New Therapies
Date and Time : April 9, 2024, 2:35 PM – 2:50 PM PDT
Location : TBD
Abstract : 6578
Poster Title : N17350 kills cancer cells, spares immune cells, and regresses CDX tumors from chemotherapy-naive and experienced patients
Session : New Targets
Date and Time : April 9, 1:30 PM – 5:00 PM PDT
Location : Section 25, Board 9
Abstract Number : 5895
About N17350 and N17465 and Their Novel Mechanism of Action
First described in research published in Cell from the lab of Onchilles’ Co-Founder Lev Becker, human neutrophils release catalytically active neutrophil elastase (called ELANE), which selectively and potently kills cancer cells independent of their genetics and anatomical origin, mobilizes adaptive immunity, and avoids resistance mechanisms. The team at Onchilles translated this ground-breaking discovery into a proprietary set of molecules, including N17350 and N17465, with the potential to treat a wide variety of tumor types with an optimal efficacy and safety profile.